Senators slam FDA for pain med approval; Lilly's Lechleiter calls for STEM education;

@FiercePharma: Here's why a crowdfunded HIV vaccine project is drawing criticism from some scientists. More | Follow @FiercePharma

@TracyStaton: Gilead won't make hep C sales projections, but doesn't mind if you do. Provided they're huge. Piece | Follow @TracyStaton

@EricPFierce: CEO Bresch's moves in India give Mylan low-cost production tied to a high-value rep. Report | Follow @EricPFierce

@CarlyHFierce: Shire steers Vyvanse toward binge eating as earnings come up aces. Article | Follow @CarlyHFierce

> The FDA has received a letter from thee top U.S. senators demanding to know why it approved hydrocodone drug Zohydro, which doesn't come with abuse-deterrent protections. Story

> GlaxoSmithKline ($GSK) is partnering with the National Institutes of Health (NIH) on developing a treatment for a rare inflammatory disease as a way to widen its respiratory lead. Story

> Eli Lilly ($LLY) CEO John Lechleiter writes in Forbes that companies need to invest in science, technology, engineering and math (STEM) education programs in U.S. public schools to get the high-tech workforce the U.S. needs. Blog

> Daiichi Sankyo and UMN Pharma have entered a collaborative research agreement for a norovirus vaccine.

Medical Device News

@FierceMedDev: Israel's Lumenis is plowing ahead with a planned $100M IPO--device market wariness be damned. Story | Follow @FierceMedDev

@MarkHFierce: Philips scored a strategically smart remote patent monitoring deal with Boston's Partners Healthcare. Article | Follow @MarkHFierce

@MichaelGFierce: This week's Chutes&Ladders: Ex-Gilead Irish operations leader joins Alexion to expand in Dublin, Athlone. Report | Follow @MichaelGFierce

@EmilyWFierce: No love for Aveo and Astellas: Companies 'breakup,' end pact to develop cancer drug. Article | Follow @EmilyWFierce

> By winning New York Dx certification, Ariosa gains a valuable marketing tool. Item

> Medtronic unveils a new treatment for peripheral artery disease in Europe. Story

> Ahead of its acquisition by Smith & Nephew, ArthroCare shows its profit. News

Biotech News

@FierceBiotech: Follow the money: Our John Carroll talks money, geography and biotech. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Rare-disease powerhouse Alexion grabs an option on muscular dystrophy buyout. More | Follow @JohnCFierce

@DamianFierce: Astellas finally bails on $AVEO, giving up on the thrice-failed tivozanib. Story | Follow @DamianFierce

@EmilyMFierce: BioLineRx shows effectiveness of leukemia drug in preclinical study. Article via FierceBiotech Research | Follow @EmilyMFierce

> AstraZeneca may have a gout blockbuster on its hands with lesinurad. Story

> GlaxoSmithKline eyes rare disease to widen its respiratory lead. Piece

And Finally... #HealthPolicyValentines is back for the third year in a row. More

Suggested Articles

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

The countdown to the FDA's first coronavirus vaccine hearing has begun, and new agency documents outline an agenda for the Thursday confab.

Black Americans’ confidence in COVID-19 vaccines is dropping, with only 43% saying they will get a vaccine once it's out—down 22 points since August.